Children were randomized to either parenteral ceftriaxone 50 mg/kg/day for 3 days followed by oral co-amoxiclav 50 mg/kg/day for 7 days (n = 258), or to co-amoxiclav 50 mg/kg/day for 10 days (n ...

To compare adverse events in ‘at risk’ children with influenza/ILI treated with co-amoxiclav versus placebo. • To develop and validate risk scores for influenza-related clinical deterioration and ...